Elevance Health, Inc. (ELV) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024. Elevance Health is a leading U.S. health insurer serving nearly 46 million medical members through affiliated plans. The company operates four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The reporting period reflects the impact of Medicaid membership attrition due to eligibility redeterminations, offset by growth in commercial and individual markets and strategic acquisitions.
Key Financial Metrics
| Metric (in millions, except per share) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Operating Revenue | $43,223 | $43,377 | $85,496 | $85,275 |
| Net Income | $2,301 | $1,856 | $4,550 | $3,860 |
| Shareholders' Net Income | $2,300 | $1,853 | $4,546 | $3,842 |
| Diluted EPS | $9.85 | $7.79 | $19.44 | $16.10 |
| Operating Cash Flow (YTD) | $2,425 | $8,419 | $2,425 | $8,419 |
| Benefit Expense Ratio | 86.3% | 86.4% | 85.9% | 86.1% |
| Debt-to-Capital Ratio | 39.6% | N/A | 39.6% | 38.9% |
Material Changes vs. Prior Period
- Profitability Growth: Net income increased 24.0% in Q2 and 17.9% YTD compared to the prior year. This was driven by improved operating gains across segments, a $240 million gain from the sale of the life and disability business, higher net investment income, and lower amortization of intangible assets.
- Membership Trends: Total medical membership declined 4.6% year-over-year to 45.8 million. This was primarily due to a 23.2% drop in Medicaid membership (2.7 million members) following eligibility redeterminations. Conversely, Individual membership grew 35.0%.
- Revenue Composition: While premiums declined due to Medicaid attrition, product revenue from CarelonRx increased due to external member growth and the acquisition of Paragon Healthcare. Premium rate increases across all lines helped offset volume declines.
- Cash Flow: Operating cash flow decreased significantly YTD ($2.4B vs $8.4B) primarily due to the timing of CMS payments received in the prior year and working capital changes related to membership declines.
Guidance, Outlook, and Risks
- Strategic Transactions: The company completed the acquisition of Paragon Healthcare (infusion services) and the sale of its life and disability business. It is pending the acquisition of Centers Plan for Healthy Living (expected Q3 2024) and has formed a joint venture (Augusta) with Clayton, Dubilier & Rice for care delivery innovation.
- Regulatory Impact: The company anticipates continued growth in commercial plans as Medicaid members exit the program. The Inflation Reduction Act provisions, including drug price negotiation and insulin caps, remain key regulatory factors.
- Star Ratings: CMS recalculated 2024 Star Ratings, increasing Elevance's enterprise enrollment-weighted average from 3.5 to 4.0 Stars, which is expected to improve bonus payments for the 2025 payment year.
- Litigation: The Blue Cross Blue Shield Antitrust Litigation subscriber settlement became effective in June 2024 after the Supreme Court declined to hear appeals. Provider litigation remains ongoing. The company is also defending against a DOJ lawsuit regarding Medicare risk adjustment data.
- Capital Allocation: The company maintains a strong liquidity position with $36.8 billion in cash and investments. It continues to repurchase shares ($1.0 billion YTD) and pay dividends ($1.63/share in Q2).
Key Facts for Investor Verification
- Medicaid Attrition Impact: Verify the sustainability of commercial growth to offset the 23.2% decline in Medicaid membership and its long-term effect on premium revenue.
- Medical Cost Trends: Monitor the benefit expense ratio (85.9% YTD) and the impact of medical cost trends on future underwriting profitability.
- Investment Portfolio: Review the $29.7 billion fixed maturity portfolio for unrealized losses ($1.26 billion gross) and potential credit impairments in a high-interest-rate environment.
- Legal Contingencies: Assess the potential financial exposure from ongoing provider antitrust litigation and the DOJ Medicare risk adjustment lawsuit.
- Integration Costs: Track the integration expenses and synergies from recent acquisitions (Paragon, BioPlus) and the new Augusta joint venture.